EPM asked several pharma industry experts what key learnings and takeaways they are taking from 2022 within pharma manufacturing.
Recipharm:
"We have seen a significant increase in demand for pre-filled syringe (PFS) sterile filling this year, which is set to continue for the foreseeable future. This is part of a broader 12% increase in demand for sterile fill & finish of complex dosage forms over the last 12 months - double that of overall aseptic filling. This is driven by a larger proportion of biologics coming through the development pipeline, which require parenteral delivery and, as a result, need aseptic processing.